Pfizer, Astellas Beat Challenge To Prostate Cancer Drug Patent
A group of 11 companies have lost their bid to nix an Astellas and Pfizer patent protecting the prostate-cancer drug Xtandi at the European Patent Office, as their method for making...To view the full article, register now.
Already a subscriber? Click here to view full article